论文部分内容阅读
目的:探讨伊贝沙坦和氨氯地平对原发性高血压的疗效及对血清游离脂肪酸(FFA)的影响。方法:采用随机对照法,将符合原发性高血压诊断的120例患者分为2组各60例,试验组给予伊贝沙坦150 mg,qd;对照组给予氨氯地平5 mg,qd。2组均分别在治疗4、8周后,观察降压效果和血清游离脂肪酸的改变。结果:治疗4周后2组有效率分别为83.3%和66.7%,差异有统计学意义(P<0.05);治疗8周后,2组有效率差异无统计学意义(P>0.05)。治疗8周前、后,试验组的FFA水平与对照组比较显著降低(P<0.05)。结论:与氨氯地平相比较,伊贝沙坦短期的降压治疗有更好的效果,且能够降低患者血清的FFA,是一种较理想的降压药。
Objective: To investigate the effect of irbesartan and amlodipine on essential hypertension and its effect on serum free fatty acid (FFA). Methods: A randomized controlled trial of 120 patients diagnosed with essential hypertension was divided into two groups of 60 patients. The experimental group was given irbesartan 150 mg qd and the control group was given amlodipine 5 mg qd. Two groups were treated 4 and 8 weeks after treatment, observed antihypertensive effect and changes in serum free fatty acids. Results: After 4 weeks of treatment, the effective rates of the two groups were 83.3% and 66.7%, respectively, with statistical significance (P <0.05). After 8 weeks of treatment, there was no significant difference in the effective rates between the two groups (P> 0.05). After 8 weeks of treatment, the FFA level of the experimental group was significantly lower than that of the control group (P <0.05). CONCLUSIONS: Compared with amlodipine, short-term antihypertensive treatment of irbesartan has a better effect and can reduce the serum FFA of patients, which is an ideal antihypertensive drug.